Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia

Molecular Pharmaceutics

Volumn 9, Issue 11, 2012, Pages 3062-3078

  Retnakumari, Archana P ^a   Hanumanthu, Prasanna Lakshmi ^a   Malarvizhi, Giridharan L ^a   Prabhu, Raghuveer ^a   Sidharthan, Neeraj ^a   Thampi, Madhavan V ^a   Menon, Deepthy ^a   Mony, Ullas ^a   Menon, Krishnakumar ^a   Keechilat, Pavithran ^a   Nair, Shantikumar ^a   Koyakutty, Manzoor ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

albumin; chronic myeloid leukemia; drug resistance; rational design; targeted nanomedicine; transferrin

Indexed keywords

BCR ABL PROTEIN; CELL SURFACE RECEPTOR; HUMAN SERUM ALBUMIN; IMATINIB; MULTIDRUG RESISTANCE PROTEIN; PROTEIN MCL 1; SORAFENIB; STAT5 PROTEIN; TRANSFERRIN RECEPTOR;

ADVANCED CANCER; ANTILEUKEMIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BLAST CELL CRISIS; CANCER STAGING; CELL MEMBRANE; CELL PROLIFERATION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONJUGATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG ACTIVITY; DRUG CONJUGATION; DRUG CYTOTOXICITY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; NANOENCAPSULATION; NANOENGINEERING; NANOMEDICINE; ONCOGENE; PARTICLE SIZE; PERSONALIZED MEDICINE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NANOMEDICINE; NANOPARTICLES; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PIPERAZINES; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TRANSFERRIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERUM ALBUMIN; STAT5 TRANSCRIPTION FACTOR; TRANSFERRIN; TUMOR CELLS, CULTURED;

EID: 84868583277     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300172e     Document Type: Article

References (48)

1. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors Nature 2009, 9, 28-39
2. Cohen, P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discovery 2002, 1, 309-315
3. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S. M.; Riggins, G. J. High frequency of mutations of the PIK3CA gene in human cancers Science 2004, 304, 554
4. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W. Mutations of the BRAF gene in human cancer Nature 2002, 417, 949-954
5. Deininger, M. W.; Goldman, J. M.; Melo, J. V. The molecular biology of chronic myeloid leukemia Blood 2000, 96, 3343-3356
6. Daley, G. Q.; Van Etten, R. A.; Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome Science 1990, 247, 824-830
7. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat. Med. 1996, 2, 561-566
8. Weisberg, E.; Griffin, J. D. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL transformed hematopoietic cell lines Blood 2000, 95, 3498-3505
9. OHare, T.; Eide, C. A.; Deininger, M. W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood 2007, 110, 2242-2249
10. Jabbour, E.; Hochhaus, A.; Cortes, J.; La Rosée, P.; Kantarjian, H. M. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history Leukemia 2010, 24, 6-12
11. Cortez, D.; Reuther, G.; Pendergast, A. M. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells Oncogene 1997, 15, 2333-2342
12. de Groot, R. P.; Raaijmakers, J. A.; Lammers, J. W.; Jove, R.; Koenderman, L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells Blood 1999, 94, 1108-1112
13. Chai, S. K.; Nichols, G. L.; Rothman, P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients J. Immunol. 1997, 159, 4720-4728
14. Gruber, F. X.; Ernst, T.; Porkka, K; Engh, R. A.; Mikkola, I.; Maier, J.; Lange, T.; Hochhaus, A. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients Leukemia 2012, 26, 172-177
15. Kindler, T.; Breitenbuecher, F.; Kasper, S.; Stevens, T.; Carius, B.; Gschaidmeier, H.; Huber, C.; Fischer, T. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C Leukemia 2003, 17, 999-1009
16. Nyman, D. W.; Campbell, K. J.; Hersh, E.; Long, K.; Richardson, K.; Trieu, V.; Desai, N.; Hawkins, M. J.; Von Hoff, D. D. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel stabilized with human serum albumin, administered weekly for 3 doses every 4 weeks in patients with advanced non-hematologic malignancies J. Clin. Oncol. 2005, 23, 7785-7793
17. Kratz, F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles J. Controlled Release 2008, 132, 171-183
18. Okabe, S.; Tauchi, T.; Ohyashiki, K. Characteristics of Dasatinib- and Imatinib-Resistant Chronic Myelogenous Leukemia Cells Clin. Cancer Res. 2008, 14, 6181-6186
19. Misra, R.; Sahoo, S. K. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells Mol. Pharmaceutics 2011, 8, 852-866
20. Gottesman, M. M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter Annu. Rev. Biochem. 1993, 62, 385-427
21. Mahon, F. X.; Belloc, F.; Lagarde, V.; Chollet, C.; Moreau-Gaudry, F.; Reiffers, J.; Goldman, J. M.; Melo, J. V. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models Blood 2003, 101, 2368-2373
22. Marx, J. L. Oncogenes amplified in cancer cells Science 1984, 223, 40-41
23. Gorre, M. E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P. N.; Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 2001, 293, 876-880
24. + human leukemia cells to the dual Abl/Src inhibitor BMS-354/825 Blood 2007, 109, 4006-4015
25. Zhu, Q. S.; Xia, L.; Mills, G. B.; Lowell, C. A.; Touw, I. P.; Corey, S. J. G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth Blood 2006, 107, 1847-1845
26. Hoelbl, A.; Schuster, C.; Kovacic, B.; Zhu, B.; Wickre, M.; Hoelzl, M. A.; Fajmann, S.; Grebien, F.; Warsch, W.; Stengl, G. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia EMBO Mol. Med. 2010, 2, 98-110
27. Kantarjian, H. M.; Giles, F.; Quintás-Cardama, A.; Cortes, J. Important Therapeutic Targets in Chronic Myelogenous Leukemia Clin. Cancer Res. 2007, 13, 1089-1097
28. Warsch, W.; Kollmann, K.; Eckelhart, E.; Fajmann, S.; Cerny-Reiterer, S.; Hölbl, A.; Gleixner, K. V.; Dworzak, M.; Mayerhofer, M.; Hoermann, G. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia Blood 2011, 117, 3409-3420
29. Rahmani, M.; Nguyen, T. K.; Dent, P.; Grant, S. The Multikinase Inhibitor Sorafenib Induces Apoptosis in Highly Imatinib Mesylate-Resistant Bcr/Abl- Human Leukemia Cells in Association with Signal Transducer and Activator of Transcription 5 Inhibition and Myeloid Cell Leukemia-1Down-Regulation Mol. Pharmacol. 2007, 72, 788-795
30. Malgorzata, N. S.; Mariusz, A. W.; Artur, S.; Paolo, S.; Toshio, K.; Bruno, C.; Tomasz, S. Signal Transducer and Activator of Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis J. Exp. Med. 1999, 189, 1229-1242
31. Sherr, C. J. Principles of tumor suppression Cell 2004, 116, 235-246
32. Meng, X. W.; Lee, S. H.; Dai, H.; Loegering, D.; Yu, C.; Flatten, K.; Schneider, P.; Dai, N. T.; Kumar, S. K.; Smith, B. D. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization J. Biol. Chem. 2007, 282, 29831-29846
33. Wang, Y.; Cai, D.; Brendel, C.; Barett, C; Erben, P; Manley, P. W; Hochhaus, A.; Neubauer, A; Burchert, A. Adaptive secretion of granulocyte-macrophage colonystimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation Blood 2007, 109, 2147-2155
34. Hoelbl, A.; Kovacic, B.; Kerenyi, M. A.; Simma, O.; Warsch, W.; Cui, Y.; Beug, H.; Hennighausen, L.; Moriggl, R.; Sexl, V. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation Blood 2006, 107, 4898-4906
35. Barabas, K.; Faulk, W. P. Transferrin receptors associate with drug resistance in cancer cells Biochem. Biophys. Res. Commun. 1993, 197, 702-708
36. Taetle, R.; Rhyner, K.; Castagnola, J.; To, D.; Mendelsohn, J. Role of Transferrin, Fe, and Transferrin Receptors Myeloid Leukemia Cell Growth: Studies with an Antitransferrin Receptor Monoclonal Antibody J. Clin. Invest. 1985, 75, 1061-1067
37. Wognum, A. W.; Krystal, G.; Eaves, C. J.; Eaves, A. C.; Lansdorp, P. M. Increased erythropoietin-receptor expression on CD34-positive bone marrow cells from patients with chronic myeloid leukemia Blood 1992, 79, 642-649
38. Cang, S.; Liu, D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia J. Hematol. Oncol. 2008, 1, 15
39. Cortes, J.; Jabbour, E.; Kantarjian, H.; Yin, C. C.; Shan, J.; OBrien, S.; Garcia-Manero, G.; Giles, F.; Breeden, M.; Reeves, N. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors Blood 2007, 110, 4005-4011
40. Zhu, B. M.; McLaughlin, S. K.; Na, R.; Liu, J.; Cui, Y.; Martin, C.; Kimura, A.; Robinson, G. W.; Andrews, N. C.; Hennighausen, L. Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression Blood 2008, 112, 2071-2080
41. Kerenyi, M. A.; Grebien, F.; Gehart, H.; Schifrer, M.; Artaker, M.; Kovacic, B.; Beug, H.; Moriggl, R.; Müllner, E. W. Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1 Blood 2008, 112, 3878-3888
42. Maham, A.; Tang, Z.; Wu, H.; Wang, J.; Lin, Y. Protein-based nanomedicine platforms for drug delivery Small 2009, 5, 1706-1721
43. Retnakumari, A.; Setua, S.; Menon, D.; Ravindran, P.; Muhammed, H.; Pradeep, T.; Nair, S.; Koyakutty, M. Molecular-receptor-specific, non-toxic, near-infrared-emitting Au cluster-protein nanoconjugates for targeted cancer imaging Nanotechnology 2010, 21, 055103-055115
44. Ghuman, J.; Zunszain, P. A.; Petitpas, I.; Bhattacharya, A. A.; Otagiri, M.; Curry, S. Structural basis of the drug-binding specificity of human serum albumin J. Mol. Biol. 2005, 353, 38-52
45. Ashokan, A.; Chandran, P.; Sadanandan, A. R.; Koduri, C. K.; Retnakumari, A. P.; Menon, D.; Nair, S.; Koyakutty, M. Development and haematotoxicological evaluation of doped hydroxyapatite based multimodal nanocontrast agent for near-infrared, magnetic resonance and X-ray contrast imaging Nanotoxicology 2012, 6, 652-666
46. Schanen, B. C.; Karakoti, A. S.; Seal, S.; Drake, D. R.; Warren, W. L.; Self, W. T. Exposure to titanium dioxide nanomaterials provokes inflammation of an in vitro human immune construct ACS Nano 2009, 3, 2523-2532
47. Shin, S. H.; Ye, M. K.; Kim, H. S.; Kang, H. S. The effects of nano-silver on the proliferation and cytokine expression by peripheral blood mononuclear cells Int. Immunopharmacol. 2007, 7, 1813-1818
48. Zhang, J. Y.; He, B.; Qu, W.; Cui, Z.; Wang, Y. B.; Zhang, H.; Wang, J. C.; Zhang, Q. Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation in vitro and in vivo J. Microencapsul. 2011, 28, 528-536